Exam 2 Pathways and enzymes Flashcards
GLUT transporters
- GLUT 1- in most tissues for basal glucose uptake
- GLUT 2- liver, intestine, and pancreas for high capacity glucose uptake (and glucose sensing in the pancreas). Independent of insulin, but insulin activates glycolysis and facilitates glucose utilization*
- GLUT 3- Brain for neuronal glucose uptake
- GLUT 4- muscle, adipose, and heart tissue for insulin-dependent glucose uptake
Hexokinase regulation
Hexokinase is inhibited by G6P; preventing it from accumulating and tying up all of the cell’s store of inorganic phosphate
Glucokinase regulation
Not inhibited by G6P like hexokinase. Glucokinase is regulated by its high Km and being bound to the glucokinase regulatory protein (GRP; promoted by F6P) in the fasted state; sequesters it in the nucleus. It is activated by higher glucose levels and by F1P mediated dissociation from GRP. Transcription in the liver is also induced by insulin (unlike hexokinase). When it is in the cytoplasm, glucokinase binds to the dephosphorylated form of F26BPase (form made from insulin activity; inactive form; b form) that keeps it in the active state (allows it to deal with the influx of glucose). Glucokinase is also inhibited by CoA thioesters and LCFAs (these are around in higher amounts in the liver when fasting occurs due to the livers consumption of them)
phosphofructokinase-1 regulation
in liver: PFK1 is regulated by insulin/glucagon mediated F2,6BP (activator) from PFK2 and deactivated by citrate. Not under AMP regulation
In muscles/RBCs: ATP inhibits PFK1 and AMP activates PFK1
- Inhibited by ATP and stimulated by ADP and AMP in non hepatic tissues
- Inhibited by citrate in the liver (from the TCA cycle)
- Inhibited by low pH- prevent further accumulation of acidic byproducts when pH is already dangerously low
- Activated by F2,6BP in liver
- Stimulated by insulin and inhibited by glucagon (liver) or stimulated by insulin (muscle)
Pyruvate kinase regulation
Activated by F1,6BP in all tissues and by ATP(-)/ADP/AMP(+) ratio in muscles and RBCs
In liver: regulated by phosphorylation from glucagon (inactivation) and feed forward activated by F1,6BP (not inhibited by ATP)
glycolysis pathway
+hexokinase/glucokinase: glucose to G6P (uses ATP)
phosphoglucoisomerase: G6P to F6P
+PFK1: F6P to F1,6BP (uses ATP)
aldolase B: F1,6BP to DHAP and G3P
triose isomerase: DHAP to G3P
G3PDH: G3P to 1,3BPG (makes NADH and uses Pi)
Phosphoglycerate kinase: 1,3BPG to 3PG (makes ATP)
PG mutase: 3PG to 2PG
Enolase: 2PG to PEP (looses H2O)
+Pyruvate kinase: PEP to pyruvate (makes ATP)
+=irreversible
gluconeogenesis pathway
+Pyruvate carboxylase (in mitochondria only): pyruvate to oxaloacetate
+PEPCK: oxaloacetate to PEP (uses GTP)
Back to F1,6BP through reversible reactions
+F1,6BPase: F1,6BP to F6P
Reversible phosphoglucoisomerase reaction
+G6Pase: G6P to glucose
+=irreversible
bifunctional protein
has 2 domains; phophofructo-2-kinase and fructose-2,6-bisphosphatase. When the enzyme is phosphorylated by cAMP dependent PKA, it acts as a phosphatase and it acts as a kinase when it is dephosphorylated. F26BP stimulates phsophofructokinase and inhibits F16BPase, so when glucagon is active, the bifunctional protein is phosphorylated and acts as a phosphatase to decrease F26BP in the cell and allow gluconeogenesis
fructose 1,6 bisphosphatase regulation
activated by: citrate and cortisol
deactivated by: AMP and F2,6BP
Glycogen metabolism regulation
Glucagon: phosphorylation by PKA leads t phosphorylated , phosphorylase kinase, which phosphorylates glycogen phosphorylase (active), phosphorylated glycogen synthase (inactive), and phosphorylated inhibitor 1 protein (inhibits protein phosphatase 1; PP1). Epinephrine has the same effects in the liver and muscle; acts independently of dietary state. In muscle,
Insulin: leads to active PKB which causes exocytosis of GLUT4 transporters in some tissues, phosphorylated PP1 (active), which dephosphorylates glycogen synthase (active), glycogen phosphorylase, and phosphorylase kinase (inactive)
Allosteric regulation: G6P activates glycogen synthase and inactivates glycogen phosphorylase. Glucose and ATP also inhibit glycogen phosphorylase.
In muscle cells, phosphorylase kinase is also activated by Ca2+ and glycogen phosphorylase is activated by AMP without the need for other activators; allows the muscle to quickly adjust to demands before other regulation can catch up
Ethanol Metabolism
- Converted to acetaldehyde tough alcohol dehydrogenase yielding NADH
- Acetaldehyde is converted to acetate in the mitochondria through acetaldehyde DH giving NADH
- This process gives a lot of NADH, so pyruvate is converted to lactate to give NAD+ through lactate DH, but in the fasted state, pyruvate is needed, so excessive drinking can lead to mild hypoglycemia because the accumulation of NADH in the mitochondria inhibits NADH shuttling to the mitochondria, leading to an increase in cytosolic NADH
- If too much NADH is accumulated, the second reaction involving the conversion of acetaldehyde is unable to proceed and acetaldehyde is responsible for the hangover through the formation of adducts with proteins and nucleic acids. Eventually resolves due to ETC use of NADH to regenerate NAD+
- NAD+ accumulation also inhibits gluconeogenesis because NAD+ is needed to oxidize lactate to pyruvate
- The final product of this, acetate, is converted to acetyl-coA and is used to synthesize fats. Chronic production of acetyl-coA leads to “fatty liver” seen in alcoholics
- When ethanol is present, there is a high amount of cytosolic and mitochondrial NADH, which ties up NAD+ and prevents conversion of lactate to pyruvate and malate to oxaloacetate which inhibits gluconeogenesis; not as much of a problem in adults as it is in children who have developing livers that are not yet efficient at this
Fructose metabolism
- can be phosphorylated to F6P by hexokinase, but its Km for fructose is very high, so it is usually converted to F1P by fructokinase in the liver
- Aldolase B (same one that cleaves F1,6BP) then cleaves F1P into DHAP and glyceraldehyde
- Glyceraldehyde is converted to G3P by triode kinase using ATP to phosphorylate it.
- Excess fructose can lead to F1P accumulation due to fructose pathway bypassing rate limiting PFK1 step and aldolase B being slower than fructokinase due to it preferring F1,6BP as a substrate. F1P activates GRP, but has no affect on PFK, so stimulates glycogen synthesis, but also ties up a large amount of inorganic phosphate. The increased glycogen levels can also lead to shunting of glucose and fructose to lactic acid and FA production over time, possibly leading to accumulation of lipids in the liver if VLDLs can’t handle the FA load; this leads to FA liver disease
- Note; fructose cannot be converted to G6P, so it can’t enter the pentose phosphate pathway or glycolysis, so it is converted to fat when in excess in the liver. (In other tissues, hexokinase is used so it can be used like glucose, but other tissues only metabolize 10% of fructose).
Galactose metabolism
- First metabolized by galactokinase which converts galactose to Gal1P using ATP. Irreversible
- Gal1P is then converted to UDP-Gal by Gal1P uridyl transferase using a UDP from a UDP glucose converting it to G1P. This reaction is reversible
- UDP-Gal is then converted to UDP-Glucose by UDP-galactose-4-epimerase. Reversible
Pyruvate dehydrogenase information
- a multi enzyme complex with 3 components. These components channel the products to the next subunit, so it does not rely on diffusion of substrate.
- Pyruvate dehydrogenase component (E1)- contains thaimine pyrophosphate as a prosthetic group (thyamine pyrophosphate is always involved in oxidative decarboxylations and most of the time involve in simple decarboxylations)
- Dihydrolipoyl transacetylase component (E2)- contain lipoic acid on a lysine side chain
- Dihydrolipoyl dehydrogenase component (E3)- contains FAD containing flavoprotein
- There is a kinase that regulates this complex at E1 by phosphorylation. This enzyme is not regulated by PKA, but by ATP
- NAD+ and CoA are also used as cosubstrates in the reaction
- Except for lipoic acid, all of these cofactors require vitamins to be produced from the diet and deficiencies lead to pyruvate accumulation and subsequent reduction to lactate or transamination to alanine
pyruvate dehydrogenase mechanism
- Pyruvate is decarboxylated and attached to thiamine pyrophosphate in E1 giving hydroxyethyl TPP
- The hydroxyethyl is released o the next enzyme E2 where the lypoyllysine is attached to this 2 carbon molecule
- Then acetyl coA is used in E2 to hydrolyze the molecule off, giving acetyl-CoA
- E3 is used to reoxidize the lipoyllysine using Fad to FADH2
- This FADH2 in E3 is oxidized by NADH which goes to the ETC and all of the cofactors are in their original states
- α-KGDH uses a similar mechanism
- PDH is inhibited by ATP, acetly-CoA, and NADH and is activated by AMP, CoA, and NAD+ and Ca+. The acetyl CoA regulation prevents accumulation of acetyl-CoA if there is not enough oxaloacetate to process it
- PDH is also covalently activated by dephosphorylation and inhibited by phosphorylation. This is done by a kinase that is activated by ATP
TCA cycle
- Acetyl-coA is transferred to a 4 carbon oxaloacetate to form citrate through the enzyme citrate synthase. This reaction is irreversible
- Citrate is then isomerize to isocitrate by aconitase. It is first dehydrated to aconitate and then hydrated to isocitrate. This is reversible but the equilibrium is strongly to the citrate side
- Isocitrate is decarboxylated to α-ketoglutarate by isocitrate dehydrogenase. This is an irreversible step and produces a CO2 and NADH
- α-ketoglutarate is then converted to succinyl-CoA by α-ketoglutarate dehydrogenase; this enzyme resembles pyruvate dehydrogenase in structure and function. CO2 and NADH are also produced here.
- Succinyl-CoA synthetase (aka succinyl thiokinase) converts succinyl-Coa to succinate. There are 2 forms of this enzyme in humans; one gives ATP and one gives GTP. The one that gives ATP predominates in the brain and heart, the GTP generating one is in the liver. Most other tissues have both in similar amounts
- Succinate dehydrogenase complex (complex II) uses FAD to convert succinate in to fumarate, giving FADH2. This is embedded in the matrix and is used in the ETC
- Fumarate is then hydrated to malate through fumarase
- Malate is oxidized to oxaloacetate through malate dehydrogenase. Another molecule of NADH is produced here
- The TCA cycle yields 3 NADH and 1 FADH2 for each turn
Pyruvate dehydrogenase regulation
- nhibited by NADH and acetyl-CoA, and is activated by NAD+, AMP, and CoA. It is also regulated by phosphorylation (inactivated). The protein that phosphorylates it is activated by the same things that inhibit pyruvate dehydrogenase (NADH and acetyl-CoA). They are also regulated by hormones, e.g. insulin inhibits pyruvate DH kinase, and allows pyruvate to oxidize pyruvate
TCA regulation: Citrate synthase
inhibited by ATP and citrate (competes with oxaloacetate for the active site)
TCA regulation: Isocitrate dehydrogenase
- nhibited by NADH and is activated by AMP and NAD+